The REQUITE abstract: "T. Rattay, et al: Development and validation of a predictive risk model for acute skin toxicity in patients undergoing breast radiotherapy" has been accepted for poster presentation at the 15th St. Gallen International Breast Cancer Conference, Primary Therapy of Early Breast Cancer Vienna, Austria 15-18 March 2017.
Tim Rattay is investigating how clinical and genetic data can be integrated to give breast cancer patients more accurate information about their individual risk of radiation side-effects.
After surgery, radiotherapy is the second most commonly used treatment for breast cancer. Radiotherapy makes a major contribution to local tumour control but sometimes causes side-effects in the body’s normal tissues. Depending on their severity, these side-effects can considerably affect breast appearance and the patient’s quality of life.
Supervised by Dr Chris Talbot, Dr G Don Jones and Professor Paul Symonds, Tim’s research project uses data from breast cancer patients enrolled in the EU-funded multi-institutional REQUITE study. The aim is to develop a predictive tool to help patients make informed choices regarding their treatment and guide surgeons in pre-operative decision-making.